Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomized, double blind, parallel group study to investigate efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.

X
Trial Profile

A multi-centre, randomized, double blind, parallel group study to investigate efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ONO 5334 (Primary) ; Alendronic acid
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Acronyms OCEAN
  • Most Recent Events

    • 05 Dec 2012 Planned number of patients changed from 265 to 285 as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Quantitative computed tomography results presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
    • 20 Sep 2011 Results assessing changes in levels of bone turnover markers presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top